The global biomarker-based disease detection market is growing rapidly, driven by rising demand for personalized medicine, early disease diagnosis, and targeted therapies. Advances in genomics, immunoassays, and next-generation sequencing are improving diagnostic accuracy. North America leads the market, while Asia Pacific shows strong growth potential due to expanding healthcare infrastructure.
According to a research study published by Knowledge Sourcing Intelligence (KSI), the biomarker-based disease detection market will expand from USD 63.5 billion in 2026 to USD 107.1 billion in 2031 at a CAGR of 11.0% during the forecast period.
The market is expected to experience significant growth because of increasing needs for early disease detection and the development of precision medicine technologies.
Access sample report or view details: https://www.knowledge-sourcing.com/report/biomarker-based-disease-detection-market
Key Market Insight & Emerging Trends:
The biomarker-based disease detection market is expanding rapidly because biomarkers serve essential functions in diagnosing diseases, predicting their course, and monitoring how patients respond to treatment. The rising demand for personalized medicine, together with targeted therapies, has resulted in increased use of biomarker-based diagnostic methods.
The development of genomics, proteomics, and molecular diagnostics has reached a new level because next-generation sequencing (NGS) and immunoassays now provide better detection capabilities for biomarkers. The rising number of chronic diseases, which include cancer, cardiovascular disorders, and metabolic conditions, has led to greater demand for diagnostic tests that deliver precise results at an early stage.
The market expansion benefits from two main factors, which are the routine use of biomarker testing in clinical settings and the increasing research and development funding. The developing world experiences market growth because of its better healthcare systems and its citizens learning about modern diagnostic methods.
North America maintained the highest market share during 2025 because its research capabilities enabled the quick implementation of new diagnostic technologies.
The reagent and kit product category-controlled market share because these items remain essential for biomarker testing throughout time.
The main technologies of the industry are immunoassays and NGS because they deliver precise results across multiple testing needs.
The oncology field leads all other areas because cancer treatment needs biomarker testing at all stages.
The biomarker-based disease detection market operates as a competitive industry where top companies direct their efforts towards developing new products and forming partnerships to enhance their market standing.
Product Type Insights: Reagents & Kits Leading Market Consumption
The reagents and kits segment became the largest market segment in 2025 because biomarker-based tests require these consumables for their implementation. The market experiences continuous demand because diagnostic testing volume increases and clinical research applications expand.
Technology Insights: Immunoassays and NGS Driving Innovation
Immunoassays remain the preferred solution because they provide dependable results and affordable methods for identifying protein-based biological markers. The adoption of next-generation sequencing (NGS) technology is increasing because it provides precise analysis of complicated genetic markers, which doctors use for high-level diagnostic purposes.
Application Insights: Oncology Dominating the Landscape
Market leadership in oncology persists because medical professionals use biomarkers to detect tumors at their initial stages, assess patient danger levels, and track treatment results. The segment expansion receives momentum from two primary elements, which include the growing worldwide cancer incidence and the rising demand for targeted cancer treatments.
Regional Highlights: North America at the Forefront, Asia Pacific Accelerating
North America retained its market dominance in 2025 because of its developed medical system, substantial research funding, and wide use of biomarker diagnostic tests. The Asia Pacific region will experience the fastest growth rate throughout the forecast period because better medical services become available, while more diseases emerge, and governments establish precision medicine programs.
Competitive Landscape
As a part of the report, the major players operating in the pharmacogenomics testing market have been covered, such as Roche Diagnostics, Thermo Fisher Scientific, Illumina, Agilent Technologies, QIAGEN, Bio-Rad Laboratories, PerkinElmer, Diagenode, Active Motif, and Abcam. The companies allocate substantial funds towards research and development activities while they work to develop new biomarker tests and establish partnerships that will speed up their innovation process. The emerging companies in the industry concentrate on creating unique biomarker testing methods and diagnostic products.
Market Segmentation
The report segments the biomarker-based disease detection market as follows:
By Product Type
Instruments
Reagents & Kits
Software & Services
By Technology
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Microarrays
Mass Spectrometry
Immunoassays
By Application
Oncology
Neurological Disorders
Autoimmune Diseases
Metabolic Disorders
Cardiovascular Diseases
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others
Companies Profiled:
Roche Diagnostics
Thermo Fisher Scientific
Illumina
Agilent Technologies
QIAGEN
Bio-Rad Laboratories
vPerkinElmer
Diagenode
Active Motif
Abcam
Explore More Reports:
Have questions?
More Press Releases
Modular AI Data Center Infrastructure Market to Reach USD 8.71 Billion by 2032, Driven by Rapid Deployment of Prefabricated AI Data Centers
The global modular AI data center infrastructure market is expanding as demand for high-density computing and faster AI infrastructure deployment increases. Prefabricated power modules, integrated cooling systems, and turnkey AI factory solutions are gaining traction among hyperscale operators and neocloud providers seeking scalable, energy-efficient infrastructure to support increasingly complex AI workloads.
Autonomous Vehicle Interior Market to Reach USD 26.53 Billion by 2031, Driven by AI-Powered Smart Cockpits and Human-Machine Interfaces
The global autonomous vehicle interior market is expanding as AI-powered smart cockpits, advanced human-machine interfaces, and occupant monitoring technologies transform in-vehicle experiences. Growing adoption of software-defined vehicle architectures, connected infotainment, and personalized cabin systems is creating opportunities for automotive suppliers as higher-level vehicle automation advances across global markets.
Data Center Silicon Photonics Market to Reach USD 23.1 Billion by 2032, Driven by AI Infrastructure and Co-Packaged Optics Adoption
The global data center silicon photonics market is expanding as AI infrastructure, hyperscale computing, and high-bandwidth networking increase demand for advanced optical connectivity. Innovations in co-packaged optics, photonic integrated circuits, and energy-efficient interconnects are creating growth opportunities, while manufacturing scalability, thermal management, and integration costs remain important industry considerations.
